Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4944.46
ONVO's Cash to Debt is ranked higher than
84% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. ONVO: 4944.46 )
ONVO' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 4944.46

Equity to Asset 0.95
ONVO's Equity to Asset is ranked higher than
99% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ONVO: 0.95 )
ONVO' s 10-Year Equity to Asset Range
Min: -7.39   Max: 0.96
Current: 0.95

-7.39
0.96
F-Score: 3
Z-Score: 97.55
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6686.22
ONVO's Operating margin (%) is ranked lower than
54% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. ONVO: -6686.22 )
ONVO' s 10-Year Operating margin (%) Range
Min: -5448.28   Max: -778.53
Current: -6686.22

-5448.28
-778.53
Net-margin (%) -6762.16
ONVO's Net-margin (%) is ranked lower than
54% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. ONVO: -6762.16 )
ONVO' s 10-Year Net-margin (%) Range
Min: -6820.05   Max: -3638.51
Current: -6762.16

-6820.05
-3638.51
ROE (%) -54.80
ONVO's ROE (%) is ranked higher than
56% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. ONVO: -54.80 )
ONVO' s 10-Year ROE (%) Range
Min: -120.28   Max: -120.28
Current: -54.8

ROA (%) -51.86
ONVO's ROA (%) is ranked higher than
56% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ONVO: -51.86 )
ONVO' s 10-Year ROA (%) Range
Min: -519.94   Max: -77.23
Current: -51.86

-519.94
-77.23
ROC (Joel Greenblatt) (%) -2627.34
ONVO's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ONVO: -2627.34 )
ONVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2628.77   Max: -2610.36
Current: -2627.34

-2628.77
-2610.36
» ONVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ONVO Guru Trades in Q4 2013

Steven Cohen 12,600 sh (New)
» More
Q1 2014

ONVO Guru Trades in Q1 2014

Paul Tudor Jones 17,792 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

ONVO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

ONVO Guru Trades in Q3 2014

Paul Tudor Jones 30,491 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.54
ONVO's P/B is ranked higher than
61% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. ONVO: 9.54 )
ONVO' s 10-Year P/B Range
Min: 8.6   Max: 113.7
Current: 9.54

8.6
113.7
P/S 1271.43
ONVO's P/S is ranked lower than
56% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. ONVO: 1271.43 )
ONVO' s 10-Year P/S Range
Min: 71   Max: 935
Current: 1271.43

71
935
EV-to-EBIT -17.55
ONVO's EV-to-EBIT is ranked higher than
56% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: -17.55 )
ONVO' s 10-Year EV-to-EBIT Range
Min: -138.4   Max: -10.9
Current: -17.55

-138.4
-10.9
Current Ratio 17.71
ONVO's Current Ratio is ranked higher than
97% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ONVO: 17.71 )
ONVO' s 10-Year Current Ratio Range
Min: 0.04   Max: 34
Current: 17.71

0.04
34
Quick Ratio 17.68
ONVO's Quick Ratio is ranked higher than
97% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ONVO: 17.68 )
ONVO' s 10-Year Quick Ratio Range
Min: 0.04   Max: 34
Current: 17.68

0.04
34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.99
ONVO's Price/Net Cash is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: 9.99 )
ONVO' s 10-Year Price/Net Cash Range
Min: 8.74   Max: 47.25
Current: 9.99

8.74
47.25
Price/Net Current Asset Value 9.99
ONVO's Price/Net Current Asset Value is ranked higher than
87% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ONVO: 9.99 )
ONVO' s 10-Year Price/Net Current Asset Value Range
Min: 8.74   Max: 47.25
Current: 9.99

8.74
47.25
Price/Tangible Book 9.55
ONVO's Price/Tangible Book is ranked higher than
70% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. ONVO: 9.55 )
ONVO' s 10-Year Price/Tangible Book Range
Min: 8.49   Max: 34.36
Current: 9.55

8.49
34.36
Earnings Yield (Greenblatt) -5.70
ONVO's Earnings Yield (Greenblatt) is ranked higher than
62% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ONVO: -5.70 )
ONVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -5.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:4OR.Germany, 0R02.UK
Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.
» More Articles for ONVO

Headlines

Articles On GuruFocus.com
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Other Websites
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 25 2014
ORGANOVO HOLDINGS, INC. Financials Nov 21 2014
Organovo to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 20 2014
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Nov 20 2014
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Nov 20 2014
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Nov 20 2014
Organovo to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 20 2014
Trading 3-D: Pro loves HPQ Nov 18 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 18 2014
Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue Nov 18 2014
Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue Nov 18 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 10 2014
Organovo Holdings, Inc. Reports Second Quarter Results Nov 10 2014
ORGANOVO HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
3-D-printed organs are on the way Nov 04 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Oct 24 2014
Lightning Round: FMC, Expedia & more Oct 10 2014
Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards Sep 30 2014
Insider Trading Alert - BIG, PF And ONVO Traded By Insiders Sep 17 2014
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK